Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors

(TheNewswire)

TORONTO and BOSTON - September 22, 2025 - The Newswire — Sernova Biotherapeutics(“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leadingregenerative medicine company focused on developing its Cell PouchBio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appointment of John L.Brooks III as Chair of the Company’s Board of Directors.

“We are honored to have John lead our Board at thisexciting time for Sernova,” said Jonathan Rigby, CEO of Sernova.“His deep experience in T1D, venture capital and buildingearly-stage companies will be invaluable as we advance our Cell PouchBio-hybrid Organ as a functional cure for T1D into the final cohort ofour ongoing phase 1 / 2 clinical trial.”

John L. Brooks III currently serves as ManagingDirector at Healthcare Capital LLC, where he advises early-stage lifescience companies and also as the CEO of Diamune that is developinginnovative IgG Fc-Fusion insulin analogs. During his career, Mr.Brooks served as the Chair and CEO of the Joslin Diabetes Center, theworld's preeminent diabetes research, clinical care, andeducation organization. Additionally, he has co-founded seven lifescience companies, including Insulet Corporation (Nasdaq; PODD),developer of the Omnipod tubeless insulin pump. He was previously afounder of Prism Venture Partners, a senior medical device executiveat Pfizer, and a senior manager at Arthur Andersen & Co. Mr.Brooks also serves on the boards of several T1D and population healthorganizations.

“I am thrilled to join Sernova at such an excitingmoment in its journey,” said Mr. Brooks. “The Cell PouchBio-hybrid Organ holds great potential for patients with T1D, and theintegration of novel immunotherapies like tegoprubart couldsignificantly improve the durability and effectiveness of islet celltransplantation. I look forward to working with the leadership teamand board to help guide Sernova as we seek to provide T1D patientswith a viable functional cure.”

Mr. Brooks holds an M.S. in Business Administration anda BBA from the University of Massachusetts at Amherst, where hegraduated cum laude. He is also a certified public accountant.

ABOUT SERNOVA BIOTHERAPEUTICS

Sernova Biotherapeutics is a clinical-stage companydeveloping regenerative medicine therapeutics combining its Cell Pouchwith human donor cells or stem-cell derived islet-like clusters incollaboration with Evotec to create bio-hybrid organs to treat T1D. Abio-hybrid organ is comprised of non-biomaterials, such as the CellPouch, integrated with living tissues to restore or enhance thefunction of a compromised organ. This innovative approach aims todeliver a potentially revolutionary treatment for patients withchronic diseases, initially focusing on T1D and thyroiddisorders.

FOR FURTHER INFORMATION, PLEASECONTACT:

David Burke VP, Investor Relations (917) 751-5713

Email: David.Burke@sernova.com

Website: https://sernova.com/

The TSX has not reviewed this news release and does notaccept responsibility for the accuracy or adequacy of this newsrelease.

FORWARD-LOOKING INFORMATION

This press release contains forward-looking statementswithin the meaning of applicable Canadian securities laws. Withrespect to the forward-looking statements contained in this pressrelease, Sernova has made numerous assumptions regarding, among otherthings: the company’s ability to secure additional financing onreasonable terms, or at all; and the ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch,including regulatory approval, the timing and results of those trials.A more complete discussion of the risks and uncertainties facingSernova appears in Sernova’s Annual Information Form for the yearended October 31, 2024, filed with Canadian securities authorities andavailable at www.sedarplus.ca, as updated by Sernova’s continuousdisclosure filings, which are available at www.sedarplus.ca. Allforward-looking statements herein are qualified in their entirety bythis cautionary statement, and Sernova disclaims any obligation torevise or update any such forward-looking statements or to publiclyannounce the result of any revisions to any of the forward-lookingstatements contained herein to reflect future results, events ordevelopments, except as required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.